Inventor
ANDREW LEBER
Inventor
US
Overview
Patents· 12 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations32%
C07DHeterocyclic compounds26%
A61KPreparations for medical, dental or toiletry purposes18%
C12NMicroorganisms or enzymes11%
A01KAnimal husbandry5%
C07BGeneral methods of organic chemistry5%
Y02ATechnologies for adaptation to climate change3%
PatentTitleYear
12,391,673LANCL ligands202512,281,096Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)202512,150,961Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith202412,145,920Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same202411,680,045NLRX1 ligands202311,597,717Substituted imidazoles as PLXDC2 ligands202311,548,885NLRX1 ligands202311,492,342Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)202211,459,310LANCL ligands202211,377,437Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same202211,197,891Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith202111,180,473PLXDC2 ligands2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2023Patents assigned to LANDOS BIOPHARMA INC (8)· patent assignee history
2021–2025Based in US· patent location history
2024–2025Patents assigned to NIMMUNE BIOPHARMA INC (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| LANDOS BIOPHARMA INC | 8 | 2021–2023 |
| NIMMUNE BIOPHARMA INC | 4 | 2024–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 12 | 2021–2025 |